The first patient has been randomized for treatment in a phase 3 trial investigating TRS01 eye drops in active noninfectious anterior uveitis, including patients with uveitic glaucoma, according to a press release from Tarsier Pharma.
TRS4VISION is a randomized, active-controlled, double-masked study investigating the safety and efficacy of TRS01. One hundred sixty-two patients are expected to be evaluated in multiple centers throughout the U.S. and Europe.
“We are proud to proceed according to previously planned time frames focusing on bringing for the first time a solution for patients